Surrozen Inc (SRZN)

Surrozen, Inc.'s stock has experienced notable movements in the past six months. As of January 7, 2026, the share price was $19.99, a 56.05% increase from January 8, 2025. Over the last 12 months, the stock price increased by 26.62%, and in the past month, it saw an 18.21% increase. However, the stock dropped 15.66% in the week leading up to January 6, 2026, despite impressive gains over the preceding six months. Key events impacting the stock include a strategic pivot to focus on its ophthalmology pipeline, discontinuing the development of SZN-043, and a private placement in March 2025, raising approximately $76.4 million to fund its ophthalmology programs. Insider buying activity was observed, with entities related to The Column Group purchasing shares worth approximately $300,296 on January 6, 2026.

As a clinical-stage biotechnology company, Surrozen, Inc.'s products are currently in development and not yet commercially available. Therefore, there is no established demand seasonality for its products and services. Demand will be driven by clinical trial outcomes, regulatory approvals, and eventual market adoption, rather than seasonal fluctuations.

Surrozen, Inc. is a clinical-stage biotechnology company focused on discovering and developing targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration. The company uses its SurroBody platform to create bispecific antibody molecules that modulate Wnt receptor activity with enhanced tissue specificity. Surrozen's pipeline includes product candidates like SZN-8141 and SZN-8143 for retinal diseases, targeting conditions like Diabetic Macular Edema and wet AMD. The development of SZN-043 for severe alcohol-associated hepatitis was discontinued due to insufficient clinical benefit. The company also has a collaboration with Boehringer Ingelheim for the development of SZN-413 for retinal vascular-associated diseases.

Surrozen, Inc. is headquartered in South San Francisco, California, and is incorporated in Delaware. Its primary operations are focused on research and development at its South San Francisco location. There is no publicly available information regarding a broader geographic footprint for product sales or extensive operational presence beyond its headquarters.

Surrozen, Inc. generally holds a positive brand reputation among analysts, receiving a consensus rating of "Moderate Buy". MarketBeat's MarketRank™ score indicates that Surrozen scored higher than 75% of companies evaluated in the medical sector. Over the past 90 days, Surrozen's stock has received one upgrade from analysts. No specific negative events significantly impacting its reputation in the past year were identified.

Surrozen, Inc. has a significant level of institutional ownership, with 52 institutional owners and shareholders holding a total of 4,875,599 shares. Institutional investors own 66.57% of Surrozen's stock, while insiders hold 43.50%. Major institutional owners include StemPoint Capital LP, VR Adviser, LLC, Ra Capital Management, L.p., 5AM Venture Management, LLC, Vanguard Group Inc, Vivo Capital, LLC, Stonepine Capital Management, LLC, Samsara BioCapital, LLC, Nantahala Capital Management, LLC, Acuta Capital Partners, Llc and Column Group LLC.